Regeneron Pharmaceuticals (REGN) Other Working Capital Changes (2009 - 2026)

Regeneron Pharmaceuticals' Other Working Capital Changes history runs 10 years deep, the most recent figure standing at $99.6 million for Q1 2026.

• On a quarterly basis, Other Working Capital Changes rose 462.71% year-over-year to $99.6 million in Q1 2026; TTM through Mar 2026 was $30.2 million, a 76.52% decrease from a year earlier, with the FY2025 full-year figure at -$51.7 million, down 122.7% from the prior year.
• Other Working Capital Changes improved to $99.6 million in Q1 2026 per REGN's latest filing, from -$3.1 million in the prior quarter.
• Across five years, Other Working Capital Changes topped out at $526.3 million in Q2 2024 and bottomed at -$252.0 million in Q3 2024.
• The 5-year median for Other Working Capital Changes is $47.9 million (2025), against an average of $73.5 million.
• Across the five-year window, Other Working Capital Changes sank 477.89% in 2023 and jumped 714.48% in 2024, its largest moves.
• Year by year, Other Working Capital Changes stood at -$59.6 million in 2022, then surged by 172.15% to $43.0 million in 2023, then sank by 149.3% to -$21.2 million in 2024, then soared by 85.38% to -$3.1 million in 2025, then surged by 3312.9% to $99.6 million in 2026.
• Per Business Quant, the three latest REGN Other Working Capital Changes figures stand at $99.6 million (Q1 2026), -$3.1 million (Q4 2025), and $76.6 million (Q3 2025).